Please select the option that best describes you:

How does neoadjuvant chemo-immunotherapy impact your decision on hypofractionation/dose fractionation for locally advanced NSCLC, now getting RT alone?  

Is 60 Gy/15 fx appropriate? Is there a volume PTV cut-off (cc) which would switch to a more fractionated approach (e.g., 60 Gy/30 fx)? Is there an area you would dose reduce (e.g., hilum or mediastinum) after neoadjuvant chemo-immunotherapy?



Answer from: Radiation Oncologist at Community Practice
Comments
Radiation Oncologist at UC San Diego School of Medicine
@Drew - when you say it is "undoubtedly superior,"...
Radiation Oncologist at UCLA | VA Greater Los Angeles Healthcare System
I wouldn't call it a dud, as it was one of the mos...
Radiation Oncologist at UC San Diego School of Medicine
Okay, maybe not a dud, but certainly doesn't suppo...
Radiation Oncologist at Mallory Radiotherapy, PLLC
I also feel like I'm missing something, as I am no...
Radiation Oncologist at UCLA | VA Greater Los Angeles Healthcare System
The p-value in Figure 2C is limited by the sample ...
Sign In or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Sign In or Register to read more

Answer from: Radiation Oncologist at Academic Institution
Comments
Radiation Oncologist at UCLA | VA Greater Los Angeles Healthcare System
The 0617 study isn't a great reference for this qu...
Radiation Oncologist at Mallory Radiotherapy, PLLC
I agree regarding the suboptimal dosing of 60/30 w...
Radiation Oncologist at UCLA | VA Greater Los Angeles Healthcare System
Well, you're not alone in thinking more of 2 Gy/d ...
Sign In or Register to read more

Answer from: Radiation Oncologist at Community Practice
Sign In or Register to read more